Manning & Napier Advisors LLC Makes New Investment in The Cooper Companies, Inc. $COO

Manning & Napier Advisors LLC purchased a new position in The Cooper Companies, Inc. (NASDAQ:COO) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 1,505,210 shares of the medical device company’s stock, valued at approximately $107,939,000. Cooper Companies accounts for approximately 1.4% of Manning & Napier Advisors LLC’s investment portfolio, making the stock its 25th biggest position.

A number of other large investors also recently modified their holdings of the business. Vega Investment Solutions acquired a new stake in Cooper Companies in the second quarter worth about $737,000. Trail Ridge Investment Advisors LLC bought a new position in Cooper Companies in the 2nd quarter valued at about $753,000. Algert Global LLC acquired a new position in Cooper Companies during the 2nd quarter valued at about $7,655,000. Asset One Wealth Management LLC bought a new stake in shares of Cooper Companies during the 2nd quarter worth about $278,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Cooper Companies during the 2nd quarter worth about $744,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Mizuho set a $85.00 price objective on shares of Cooper Companies and gave the company an “outperform” rating in a report on Thursday, June 4th. Weiss Ratings cut Cooper Companies from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, June 8th. Wells Fargo & Company restated a “sell” rating and issued a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. Citigroup restated a “neutral” rating and issued a $80.00 target price (up from $76.00) on shares of Cooper Companies in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. decreased their price target on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Cooper Companies presently has an average rating of “Hold” and a consensus price target of $81.64.

Cooper Companies Trading Down 0.6%

Cooper Companies stock opened at $75.80 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The firm has a market cap of $14.78 billion, a price-to-earnings ratio of 64.24, a price-to-earnings-growth ratio of 1.99 and a beta of 0.83. The Cooper Companies, Inc. has a 1 year low of $58.89 and a 1 year high of $89.83. The firm’s 50 day moving average price is $72.09 and its two-hundred day moving average price is $71.07.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.11. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The company’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. On average, research analysts predict that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.